Toggle Health Problems and D

Reversal of cognitive decline with multitherapy (not monotherapy) – Sept 2014

Reversal of cognitive decline: A novel therapeutic program

Aging: Volume 6, Issue 9 pp 707—717 10.18632/aging.100690
Dale E. Bredesen 1, 2
1 Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095;
2 Buck Institute for Research on Aging, Novato, CA 94945


Vitamin D is just one of many therapies he used to reverse cognitive decline
I have long thought that multiptherpy would be better than monotherapy
Many of the diseases which vitamin D has been proven to treat are also treated by
   Magnesium (which also increases Vitamin D)
   Vitamin K2 (this study),
   Omega-3 (which also increases Vitamin D)
   Boron (which also increases Vitamin D)
   Posit (this study),
   Resveratrol ( (which also increases Vitamin D, this study)
   Zinc (essential for Vitamin D, this study)
See also VitaminDWiki

Overview Alzheimer's-Cognition and Vitamin D starts with the following summary

Subsequent papers by the same author

 Download the PDF from VitaminDWiki

Image Image Image

This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND).
The first 10 patients who have utilized this program include patients with memory loss associated with

  • Alzheimer's disease (AD), a
  • mnestic mild cognitive impairment (aMCI), or
  • subjective cognitive impairment (SCI).

Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD.
Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance.

Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement.
These results suggest that a larger, more extensive trial of this therapeutic program is warranted.
The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes.

Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.

Attached files

ID Name Comment Uploaded Size Downloads
7569 Reversal 3.jpg admin 25 Dec, 2016 14:18 71.73 Kb 767
7568 Reversal 2.jpg admin 25 Dec, 2016 14:17 102.60 Kb 880
7567 Reversal 1.jpg admin 25 Dec, 2016 14:16 100.15 Kb 911
7566 Inhalational Alzheimer's disease.pdf PDF 2016 admin 25 Dec, 2016 13:50 685.75 Kb 662
7565 Reversal of cognitive decline in Alzheimer's disease.pdf PDF 2016 admin 25 Dec, 2016 13:46 528.97 Kb 690
7564 Reversal of cognitive decline.pdf PDF admin 25 Dec, 2016 13:33 794.33 Kb 749